The US FTC brings a law suit in the pharmaceutical sector for monopolization based on a patent litigation (AndroGel II)

The Federal Trade Commission has brought its first suit alleging anticompetitive conduct in connection with the prosecution and settlement of pharmaceutical patent litigation since the Supreme Court’s June 2013 decision in FTC v. Actavis. Although two commissioners dissented from the decision to issue the complaint (Ohlhausen and Wright), the action reveals that the Commission’s interest in scrutinizing settlements between innovator pharmaceutical companies and generic companies remains high. In particular, this action appears to signal an expansion of the Commission’s enforcement to settlements involving non-cash consideration as “payment” for delayed entry under Actavis and a strategy to couple that challenge with an allegation of sham litigation. ANDROGEL I (AKA ACTAVIS) In June 2013,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)

Quotation

Thomas O. Barnett, Deborah A. Garza, John D. Graubert, Timothy C. Hester, Andrew D. Lazerow, John W. Nields, James J. O'Connell, The US FTC brings a law suit in the pharmaceutical sector for monopolization based on a patent litigation (AndroGel II), 26 September 2014, e-Competitions September 2014, Art. N° 95765

Visites 25

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues